States target pharmacy benefit managers with new laws to lower prescription drug costs
By
John Hanna
Summary
States across the U.S. are passing laws to regulate pharmacy benefit managers (PBMs) — middlemen that manage prescription drug coverage for health insurers — in an effort to lower medication costs for consumers. At least a dozen states enacted legislation this year limiting PBM compensation and setting minimum payments. CVS Health Corp., which operates a major PBM and also owns retail pharmacies, has spent millions fighting these regulations and filed a federal lawsuit arguing a new Tennessee law could force it to close all 136 of its pharmacies there by July 2028. The issue is politically charged ahead of midterm elections, with affordability remaining a key voter concern.
Source
Key quotes
· 3 pulledAffordability is a key issue ahead of this year's midterm elections.
CVS Health Corp. operates a large pharmacy benefit manager and says a new Tennessee law could force CVS to close all 136 of its retail pharmacies there in July 2028.
Legislators in at least a dozen states passed laws this year to limit compensation to the companies, set minimum payments from the companies to pharmacies.
You might also wanna read
Research Reveals Persistent Drug Pricing Distortions from PBM-Owned Pharmaceutical Companies
The article examines the persistent distortions in U.S. drug pricing, particularly focusing on vertically integrated pharmacy benefit manage
Senators Investigate Pharmaceutical Companies' Direct-to-Consumer Telehealth Platforms for Steering Patients to High-Cost Drugs
U.S. senators are investigating direct-to-consumer (DTC) telehealth platforms operated by pharmaceutical companies like Eli Lilly and Pfizer
arstechnica.com·4mo agoFDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·7mo ago
TrumpRx Website Launches for Direct-to-Consumer Prescription Drug Sales
The article announces the launch of TrumpRx, a government-run website where drug manufacturers will sell prescription medicines directly to
U.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
CFPB Deregulation Under Trump Benefits Major Corporations Like Toyota, Walmart, and Apple
The article reports on how under President Donald Trump, acting CFPB head Russell Vought has aggressively deregulated the Consumer Financial

Comments
Sign in to join the conversation.
No comments yet. Be the first.